Spero Therapeutics, Inc. (NASDAQ:SPRO) Director Sells $53,990.82 in Stock

Spero Therapeutics, Inc. (NASDAQ:SPRO) Director Ankit Mahadevia sold 69,219 shares of the business’s stock in a transaction on Wednesday, February 5th. The stock was sold at an average price of $0.78, for a total value of $53,990.82. Following the completion of the transaction, the director now directly owns 689,866 shares of the company’s stock, valued at approximately $538,095.48. The trade was a 9.12 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

Spero Therapeutics Stock Performance

Spero Therapeutics stock opened at $0.86 on Friday. The stock has a market cap of $47.07 million, a PE ratio of 12.33 and a beta of 0.61. The stock has a 50-day moving average of $0.99 and a two-hundred day moving average of $1.19. Spero Therapeutics, Inc. has a one year low of $0.74 and a one year high of $1.89.

Wall Street Analysts Forecast Growth

SPRO has been the topic of several analyst reports. Evercore ISI lowered Spero Therapeutics from an “outperform” rating to an “in-line” rating and set a $5.00 target price on the stock. in a research note on Friday, December 20th. TD Cowen reaffirmed a “hold” rating on shares of Spero Therapeutics in a research report on Monday, November 18th. Cantor Fitzgerald reissued an “overweight” rating on shares of Spero Therapeutics in a research report on Friday, November 15th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $5.00 price target on shares of Spero Therapeutics in a report on Thursday, January 30th.

About Spero Therapeutics

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company’s product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease.